eli lilly pill glp 1 Gets Speedy FDA Nod for Oral GLP-1 Drug, a Competitor to New Novo Nordisk Eli Lilly's Foundayo GLP-1 Weight

Final Thoughts As GLP-1 therapies continue to reshape the obesity treatment landscape, the differences between employers and health plans are meaningful

Jiang Y, Zhu H, Gong F

Lets talk about how this might workand what the science says

Having these criteria defined before starting treatment removes the pressure of making judgment calls in the moment

Additionally, weight loss is often accompanied by a reduction in basal metabolic rate (BMR) the amount of energy the body expends at rest

they are prepared per individual prescription and are not reviewed by FDA for safety, effectiveness, or quality FDA regulatory context as of June 2026: The semaglutide shortage was declared resolved in February 2025